3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
3
Conditions
Carcinoma, Non-Small-Cell Lung
211
Lung Neoplasms
77
Triple Negative Breast Neoplasms
67
Breast Neoplasms
67
Ovarian Neoplasms
53
Squamous Cell Carcinoma of Head and Neck
49
Small Cell Lung Carcinoma
47
Fallopian Tube Neoplasms
34
Endometrial Neoplasms
34
Neoplasms
31
Parkinson Disease 4, Autosomal Dominant Lewy Body
28
Neoplasm Metastasis
28
Head and Neck Neoplasms
24
Prostatic Neoplasms
20
Esophageal Neoplasms
18
Carcinoma
18
Urinary Bladder Neoplasms
16
Colorectal Neoplasms
16
Uterine Cervical Neoplasms
14
Oropharyngeal Neoplasms
14
Carcinoma, Transitional Cell
14
Carcinoma, Squamous Cell
14
Esophageal Squamous Cell Carcinoma
12
Brain Neoplasms
12
Stomach Neoplasms
10
Pancreatic Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
10
Mouth Neoplasms
9
Laryngeal Neoplasms
9
Advanced Solid Tumors
9
Interventions
Paclitaxel
8
Hyperthermic Intraperitoneal Chemotherapy
6
Mitomycin
5
Cisplatin
5
Fluorouracil
4
Bevacizumab
4
Oxaliplatin
3
Leucovorin
3
Doxorubicin
3
Cytoreduction Surgical Procedures
3
Carboplatin
3
Blood Specimen Collection
3
sodium thiosulfate
2
pembrolizumab
2
Standard of Care
2
Laparoscopy
2
soluble LAG-3 protein, human
1
relacorilant
1
oregovomab
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
dehydroftorafur
1
avelumab
1
X-Rays
1
Topotecan
1
Taxes
1
Specimen Handling
1
Saline Solution
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Peritoneal Neoplasms
×
Carboplatin
×
1 year
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts
NCT04498117
2026-04-01
FLORA-5
CanariaBio Inc.
Phase 3
Active not recruiting
615 enrolled